passiv
serotherapi
confer
immedi
protect
microbi
infect
method
rapidli
gener
human
neutral
monoclon
antibodi
yet
avail
develop
improv
method
epsteinbarr
viru
transform
human
b
cell
use
method
analyz
memori
repertoir
patient
recov
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
isol
monoclon
antibodi
specif
differ
viral
protein
includ
antibodi
vitro
neutral
activ
rang
one
antibodi
confer
protect
vivo
mous
model
sarscov
infect
result
show
possibl
interrog
memori
repertoir
immun
donor
rapidli
effici
isol
neutral
antibodi
select
cours
natur
infect
result
antibodi
respons
patient
recov
sarscov
infect
analyz
use
three
assay
elisa
use
sdsextract
viral
protein
ii
stain
babi
hamster
kidney
bhk
cell
transfect
sarscov
spike
mrna
iii
neutral
emerg
spread
new
pathogen
risk
bioterror
repres
continu
threat
human
health
vaccin
confer
activ
sustain
protect
develop
new
vaccin
slow
process
vaccin
effect
prevent
set
practic
administ
polyclon
immunoglobulin
hyperimmun
sera
anim
human
origin
introduc
behr
kitasato
use
extens
prophylact
well
therapeut
set
howev
sever
problem
associ
use
polyclon
sera
antigen
heterolog
protein
difficulti
find
immun
donor
risk
relat
use
human
blood
product
monoclon
antibodi
repres
ideal
altern
hyperimmun
sera
earli
work
show
human
monoclon
antibodi
produc
immort
b
cell
epsteinbarr
viru
ebv
fuse
b
cell
appropri
partner
produc
hybridoma
howev
method
low
effici
therefor
altern
strategi
develop
includ
human
murin
monoclon
antibodi
protein
engin
ii
select
antibodi
phagedisplay
librari
human
antibodi
fragment
iii
immun
transgen
mice
carri
human
immunoglobulin
loci
follow
product
monoclon
antibodi
use
hybridoma
technolog
although
method
led
develop
sever
therapeut
monoclon
antibodi
cytokin
surfac
molecul
impact
infecti
diseas
therapi
less
pronounc
inde
number
therapeut
antibodi
infecti
agent
still
limit
one
current
use
prevent
respiratori
syncyti
viru
rsv
infect
newborn
outbreak
sar
march
caus
sarscov
repres
recent
threat
human
health
viru
highli
contagi
clinic
cours
sever
high
mortal
rate
although
product
vaccin
remain
longterm
goal
benefit
vaccin
expect
larg
proport
popul
immun
howev
low
incid
new
case
sar
suggest
largescal
vaccin
may
best
mean
control
diseas
spread
sar
outbreak
passiv
serotherapi
potenti
provid
immedi
protect
infect
contact
medic
personnel
cure
infect
individu
also
possibl
human
sera
contain
antibodi
sarscov
avail
suffici
amount
consid
product
human
monoclon
antibodi
use
improv
method
ebv
transform
immort
memori
b
cell
patient
recov
sarscov
infect
isol
sever
monoclon
antibodi
high
viral
neutral
activ
vitro
vivo
sarscov
infect
vero
cell
serum
collect
patient
differ
time
point
infect
score
posit
three
assay
see
supplementari
tabl
onlin
wherea
sera
uninfect
individu
nonreact
antibodi
detect
elisa
stain
spiketransfect
highest
month
infect
decreas
onethird
month
contrast
neutral
antibodi
remain
constant
titer
isotyp
antibodi
detect
elisa
spikebind
assay
base
data
focus
igg
memori
b
lymphocyt
cell
isol
combin
magnet
fluorescenceactiv
cell
sort
immort
ebv
presenc
irradi
mononuclear
cell
cpg
oligonucleotid
cpg
ref
act
polyclon
activ
memori
b
cell
found
addit
cpg
increas
effici
b
cell
immort
replic
cultur
contain
igg
memori
b
cell
set
cultur
supernat
analyz
presenc
specif
antibodi
week
tabl
fraction
cultur
produc
antibodi
detect
elisa
high
month
infect
virtual
everi
second
cultur
score
posit
consist
precursor
frequenc
decreas
month
frequenc
cultur
produc
antibodi
stain
spiketransfect
cell
could
measur
month
time
point
lower
sustain
supernat
stain
spiketransfect
cell
show
neutral
activ
overal
poor
correl
stain
neutral
see
supplementari
fig
result
indic
small
fraction
memori
b
cell
specif
sarscov
antigen
direct
neutral
epitop
present
spike
protein
ebvb
cell
cultur
produc
antibodi
desir
specif
clone
limit
dilut
presenc
irradi
mononuclear
cell
addit
cpg
increas
clone
effici
attempt
led
isol
one
clone
produc
antibodi
select
specif
tabl
ebv
clone
stabl
monoclon
antibodi
recov
cultur
supernat
concentr
sever
clone
score
posit
elisa
produc
antibodi
specif
sar
nucleoprotein
np
wherea
other
recogn
np
stain
sarscovinfect
cell
expect
none
antibodi
show
neutral
activ
initi
attempt
isol
neutral
monoclon
antibodi
limit
use
viral
neutral
assay
requir
biosafeti
level
laboratori
nonetheless
cultur
show
neutral
titer
identifi
first
screen
clone
one
result
clone
produc
neutral
monoclon
antibodi
purifi
cultur
supernat
test
capac
neutral
sarscov
antibodi
neutral
tcid
sarscov
concentr
ngml
potenc
greater
convalesc
serum
fig
furthermor
neutral
effici
frankfurt
urbani
isol
data
shown
decor
spike
sarscov
detect
immunoelectron
microscopi
fig
later
avail
sarscov
spike
transfect
provid
effici
prescreen
method
approxim
antibodi
stain
spiketransfect
cell
also
neutral
homolog
viru
volum
number
august
natur
medicin
tabl
supplementari
fig
effici
stain
transfect
low
immunoglobulin
concentr
consist
highavid
bind
show
neutral
titer
proport
level
stain
contrast
antibodi
stain
poorli
high
immunoglobulin
concentr
consist
lowavid
bind
show
effici
neutral
even
immunoglobulin
concentr
spike
stain
hardli
detect
final
antibodi
concentr
capabl
complet
neutral
sarscov
infect
vitro
rang
ngml
tabl
result
show
method
describ
improv
ebv
immort
rapidli
produc
batteri
human
monoclon
antibodi
potent
neutral
capac
subnanomolar
rang
vivo
neutral
activ
antibodi
test
mous
model
acut
sarscov
infect
grade
amount
purifi
monoclon
antibodi
transfer
naiv
mice
intraperiton
inject
determin
whether
antibodi
alon
could
prevent
replic
sarscov
respiratori
tract
human
monoclon
antibodi
irrelev
specif
use
neg
control
mice
receiv
intranas
challeng
dose
tcid
sarscov
tabl
mice
receiv
monoclon
antibodi
protect
replic
challeng
viru
particularli
lower
respiratori
tract
signific
p
restrict
viru
replic
upper
respiratori
tract
note
mice
receiv
highest
dose
monoclon
antibodi
result
show
improv
ebv
transform
memori
b
cell
lead
rapid
effici
isol
candid
therapeut
monoclon
antibodi
studi
demonstr
improv
method
b
cell
immort
ebv
involv
addit
polyclon
b
cell
activ
shown
method
possibl
interrog
memori
b
cell
repertoir
sar
convalesc
patient
isol
high
effici
b
cell
clone
produc
neutral
monoclon
antibodi
procedur
rapid
complet
less
month
allow
screen
larg
repertoir
antigenspecif
memori
b
cell
favor
affin
specif
high
proport
antigenspecif
peripher
blood
memori
b
cell
found
sar
convalesc
patient
prerequisit
isol
human
monoclon
antibodi
inde
memori
b
lymphocyt
maintain
individu
lifetim
level
correl
sustain
serum
antibodi
concentr
consequ
memori
b
cell
pool
interrog
time
prime
limit
factor
total
number
cell
need
screen
access
enough
specif
exampl
abl
isol
neutral
monoclon
antibodi
specif
measl
viru
blood
sampl
obtain
year
infect
et
unpublish
data
high
effici
ebv
immort
clone
obtain
presenc
polyclon
activ
instrument
isol
sever
monoclon
antibodi
specif
sarscov
monoclon
antibodi
isol
use
elisa
recogn
np
viral
protein
neutral
viru
inde
fraction
memori
b
cell
recogn
denatur
viral
protein
exceed
fraction
b
cell
recogn
nativ
spike
protein
furthermor
antibodi
stain
spiketransfect
cell
show
neutral
activ
possibl
recogn
epitop
avail
spike
trimer
find
indic
human
b
cell
respons
direct
nonprotect
epitop
initi
screen
neutral
antibodi
led
isol
clone
clone
test
anim
model
subsequ
develop
spikebind
assay
allow
much
rapid
identif
neutral
candid
led
isol
antibodi
neutral
capac
higher
neutral
monoclon
antibodi
compar
spike
stain
neutral
activ
two
pattern
emerg
fig
antibodi
show
highavid
bind
spike
transfect
neutral
titer
proport
degre
bind
contrast
antibodi
show
lowavid
bind
spite
effici
viral
neutral
possibl
former
recogn
expos
epitop
within
receptor
bind
domain
spike
protein
wherea
latter
recogn
epitop
within
domain
expos
viral
fusion
may
poorli
access
transfect
cell
altern
possibl
spike
molecul
may
differenti
assembl
viral
particl
compar
bhk
cell
may
explain
lack
correl
stain
neutral
well
find
antibodi
neutral
viru
concentr
stain
hardli
detect
studi
includ
assess
direct
bind
viral
particl
analysi
escap
mutant
epitop
map
use
synthet
peptid
requir
elucid
antibodi
spike
protein
neutral
sarscov
infect
vivo
neutral
activ
monoclon
antibodi
test
mous
model
acut
sar
infect
intraperiton
inject
littl
antibodi
complet
protect
mice
viral
replic
lower
respiratori
tract
wherea
restrict
viru
replic
observ
upper
respiratori
tract
observ
viral
replic
effect
prevent
lower
respiratori
tract
upper
respiratori
tract
consist
find
similar
passiv
transfer
experi
influenza
virus
respiratori
syncyti
viru
conclus
describ
method
rapid
effici
isol
neutral
antibodi
emerg
pathogen
method
offer
two
uniqu
featur
first
antibodi
produc
immort
memori
b
lymphocyt
stabl
lifetim
easili
isol
peripher
blood
bypass
need
antigen
boost
requir
gener
hybridoma
second
antibodi
isol
prime
natur
host
surviv
natur
infect
elimin
need
immun
experiment
anim
may
show
differ
suscept
therefor
differ
immun
respons
method
deliv
larg
number
antibodi
immedi
select
favor
profil
accord
criteria
affin
epitop
specif
propens
gener
escap
mutant
inform
consent
obtain
peripher
blood
collect
patient
recov
infect
sarscov
igg
memori
b
cell
isol
bind
microbead
miltenyi
follow
deplet
cell
carri
igm
igd
iga
cell
sort
memori
b
cell
seed
cell
per
well
ubottom
micropl
complet
medium
contain
cpg
presenc
ebv
supernat
cell
irradi
allogen
mononuclear
cell
per
well
week
cultur
supernat
screen
specif
antibodi
posit
cultur
clone
limit
dilut
presenc
cpg
irradi
mononuclear
cell
antibodi
purifi
cultur
supernat
affin
chromatographi
protein
column
amersham
elisa
frankfurt
isol
sarscov
genbank
access
number
provid
hw
doerr
univers
frankfurt
cell
cultur
supernat
infect
vero
cell
collect
clarifi
centrifug
rpm
min
centrifug
sucros
cushion
rpm
h
beckman
rotor
pellet
purifi
use
potassium
tartrateglycerol
gradient
resuspend
tne
buffer
mm
trishcl
ph
nacl
mm
edta
protein
concentr
approxim
mg
per
ml
antigen
suspens
use
elisa
prepar
ad
sd
viral
pellet
boil
mixtur
min
elisa
plate
nunc
coat
sarscov
antigen
sodium
phosphat
buffer
ph
serial
dilut
serum
antibodi
supernat
ad
h
antibodi
bound
reveal
use
isotypespecif
secondari
antibodi
coupl
alkalin
phosphatas
vitro
neutral
assay
sera
cultur
supernat
dilut
step
mix
equal
volum
medium
contain
tcid
sarscov
viru
titer
determin
accord
method
karber
mixtur
allow
sit
min
room
temperatur
vero
cell
per
ml
ad
cultur
incub
assay
perform
biosafeti
level
laboratori
neutral
titer
indic
last
antibodi
dilut
complet
prevent
cytopath
effect
sarscov
neutral
antibodi
concentr
indic
final
antibodi
concentr
ngml
cultur
complet
protect
observ
transient
express
spike
protein
sarscov
cdna
prepar
total
sarscov
rna
use
random
primer
code
region
spike
protein
amplifi
pcr
forward
revers
pcr
primer
overlap
nucleotid
termini
respect
spike
protein
code
region
genbank
access
number
ensur
translat
eukaryot
cell
canon
kozak
sequenc
includ
front
protein
start
codon
amplifi
fragment
insert
alphaviru
vector
describ
recombin
plasmid
vcrssp
transcrib
vitro
use
mmessag
mmachin
kit
ambion
rna
obtain
plasmid
dna
reaction
mix
million
bhk
cell
ml
pb
cell
electropor
use
genepuls
biorad
twice
condit
volum
number
august
natur
medicin
figur
bind
neutral
capac
monoclon
antibodi
specif
sarscov
spike
shown
stain
bhk
cell
transfect
sarscov
spike
mrna
serial
dilut
ten
neutral
monoclon
antibodi
symbol
indic
neutral
titer
antibodi
dilut
ad
neutral
assay
gave
complet
viral
neutral
